{"id":589524,"date":"2024-11-05T21:08:31","date_gmt":"2024-11-05T21:08:31","guid":{"rendered":"https:\/\/pdfstandards.shop\/product\/uncategorized\/iso-130222012\/"},"modified":"2024-11-05T21:08:31","modified_gmt":"2024-11-05T21:08:31","slug":"iso-130222012","status":"publish","type":"product","link":"https:\/\/pdfstandards.shop\/product\/publishers\/iso\/iso-130222012\/","title":{"rendered":"ISO 13022:2012"},"content":{"rendered":"

This International Standard specifies requirements and guidance for processing practices and managing risk<\/p>\n

associated with viable cellular components of products regulated as medicinal products, biologics, medical<\/p>\n

devices and active implantable medical devices, or combinations thereof. It covers viable human materials of<\/p>\n

autologous as well as allogeneic human origin, obtained from living or deceased donors.<\/p>\n

For manufacturers of medical products containing viable cells of human origin, this International Standard<\/p>\n

specifies procedures to be used in processing and handling, as well as those to be used in identifying the<\/p>\n

hazards and hazardous situations associated with such cells, in order to estimate and evaluate the resulting<\/p>\n

risks, to control these risks, and to monitor the effectiveness of that control. Furthermore, this International<\/p>\n

Standard outlines the decision process for the residual risk acceptability, taking into account the balance of<\/p>\n

residual risk and expected medical benefit as compared to available alternatives.<\/p>\n

This International Standard provides requirements and guidance on risk management related to the hazards<\/p>\n

typical of medical products manufactured utilizing viable human materials, such as:<\/p>\n

a) contamination by bacteria, moulds, yeasts or parasites;<\/p>\n

b) contamination by viruses;<\/p>\n

c) contamination by agents causing Transmissible Spongiform Encephalopathies (TSE);<\/p>\n

d) contaminating material responsible for undesired pyrogenic, immunological or toxicological reactions;<\/p>\n

e) decomposition of the product and degradation products caused by inadequate handling;<\/p>\n

f) hazards related to the tumorigenic potential of the cell types used;<\/p>\n

g) complications resulting from unintended physiological and anatomical consequences (this includes<\/p>\n

unintended migration of cells, unwanted release of biologically active substances such as hormones and<\/p>\n

cytokines, and unintended interactions between cellular and non-cellular components of the product);<\/p>\n

h) failure of traceability;<\/p>\n

i) complications resulting from the material eliciting an unintended immunogenic reaction.<\/p>\n

For the evaluation of contamination with other unclassified pathogenic entities, similar principles might be applicable.<\/p>\n

Hazards related to genetic modification are outside the scope of this International Standard and are<\/p>\n

addressed elsewhere.<\/p>\n

NOTE 1 A definition of "genetically modified" can be found in ASTM F2312.<\/p>\n

NOTE 2 This International Standard does not specify a quality management system for the control of all stages of<\/p>\n

production of medical products as described above.<\/p>\n

If additional national or regional criteria beyond what is defined in this International Standard exist in the<\/p>\n

country where the medical product will be used, they are also applicable.<\/p>\n

NOTE 3 Regional requirements can be more stringent than requirements referenced in this International Standard,<\/p>\n

especially with regard to donor eligibility criteria.<\/p>\n

This International Standard is not applicable to:<\/p>\n

\u2014 non-viable materials of human origin;<\/p>\n

\u2014 viable cells of non-human origin;<\/p>\n

\u2014 blood and its components used for transfusion, germ cells, organs and bone marrow used for transplantation,<\/p>\n

and other tissues that do not meet the definition of "medical product";<\/p>\n

\u2014 in vitro <\/i>diagnostic devices.<\/p>\n

NOTE 4 For guidance on the application of this International Standard, see Annex A.<\/p>\n","protected":false},"excerpt":{"rendered":"

Medical products containing viable human cells \u2014 Application of risk management and requirements for processing practices<\/b><\/p>\n\n\n\n\n
Published By<\/td>\nPublication Date<\/td>\nNumber of Pages<\/td>\n<\/tr>\n
ISO<\/b><\/a><\/td>\n2012-04<\/td>\n56<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n","protected":false},"featured_media":589537,"template":"","meta":{"rank_math_lock_modified_date":false,"ep_exclude_from_search":false},"product_cat":[162,2634],"product_tag":[],"class_list":{"0":"post-589524","1":"product","2":"type-product","3":"status-publish","4":"has-post-thumbnail","6":"product_cat-11-100-20","7":"product_cat-iso","9":"first","10":"instock","11":"sold-individually","12":"shipping-taxable","13":"purchasable","14":"product-type-simple"},"_links":{"self":[{"href":"https:\/\/pdfstandards.shop\/wp-json\/wp\/v2\/product\/589524","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pdfstandards.shop\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/pdfstandards.shop\/wp-json\/wp\/v2\/types\/product"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pdfstandards.shop\/wp-json\/wp\/v2\/media\/589537"}],"wp:attachment":[{"href":"https:\/\/pdfstandards.shop\/wp-json\/wp\/v2\/media?parent=589524"}],"wp:term":[{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/pdfstandards.shop\/wp-json\/wp\/v2\/product_cat?post=589524"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/pdfstandards.shop\/wp-json\/wp\/v2\/product_tag?post=589524"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}